» Articles » PMID: 21756311

Mechanism of HCV's Resistance to IFN-α in Cell Culture Involves Expression of Functional IFN-α Receptor 1

Overview
Journal Virol J
Publisher Biomed Central
Specialty Microbiology
Date 2011 Jul 16
PMID 21756311
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms underlying the Hepatitis C virus (HCV) resistance to interferon alpha (IFN-α) are not fully understood. We used IFN-α resistant HCV replicon cell lines and an infectious HCV cell culture system to elucidate the mechanisms of IFN-α resistance in cell culture. The IFN-α resistance mechanism of the replicon cells were addressed by a complementation study that utilized the full-length plasmid clones of IFN-α receptor 1 (IFNAR1), IFN-α receptor 2 (IFNAR2), Jak1, Tyk2, Stat1, Stat2 and the ISRE-luciferase reporter plasmid. We demonstrated that the expression of the full-length IFNAR1 clone alone restored the defective Jak-Stat signaling as well as Stat1, Stat2 and Stat3 phosphorylation, nuclear translocation and antiviral response against HCV in all IFN-α resistant cell lines (R-15, R-17 and R-24) used in this study. Moreover RT-PCR, Southern blotting and DNA sequence analysis revealed that the cells from both R-15 and R-24 series of IFN-α resistant cells have 58 amino acid deletions in the extracellular sub domain 1 (SD1) of IFNAR1. In addition, cells from the R-17 series have 50 amino acids deletion in the sub domain 4 (SD4) of IFNAR1 protein leading to impaired activation of Tyk2 kinase. Using an infectious HCV cell culture model we show here that viral replication in the infected Huh-7 cells is relatively resistant to exogenous IFN-α. HCV infection itself induces defective Jak-Stat signaling and impairs Stat1 and Stat2 phosphorylation by down regulation of the cell surface expression of IFNAR1 through the endoplasmic reticulum (ER) stress mechanisms. The results of this study suggest that expression of cell surface IFNAR1 is critical for the response of HCV to exogenous IFN-α.

Citing Articles

Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response.

Dash S, Chava S, Aydin Y, Chandra P, Ferraris P, Chen W Viruses. 2016; 8(5).

PMID: 27223299 PMC: 4885105. DOI: 10.3390/v8050150.


IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.

Aboulnasr F, Hazari S, Nayak S, Chandra P, Panigrahi R, Ferraris P PLoS One. 2015; 10(12):e0141655.

PMID: 26657215 PMC: 4686105. DOI: 10.1371/journal.pone.0141655.


Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1.

Panigrahi R, Chandra P, Ferraris P, Kurt R, Song K, Garry R J Virol. 2014; 89(1):626-42.

PMID: 25339775 PMC: 4301154. DOI: 10.1128/JVI.02492-14.


Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.

Chandra P, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B PLoS One. 2014; 9(9):e108616.

PMID: 25265476 PMC: 4180933. DOI: 10.1371/journal.pone.0108616.


HCV infection selectively impairs type I but not type III IFN signaling.

Chandra P, Bao L, Song K, Aboulnasr F, Baker D, Shores N Am J Pathol. 2013; 184(1):214-29.

PMID: 24215913 PMC: 3873489. DOI: 10.1016/j.ajpath.2013.10.005.


References
1.
Cajean-Feroldi C, Nosal F, Nardeux P, Gallet X, Guymarho J, Baychelier F . Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity. Biochemistry. 2004; 43(39):12498-512. DOI: 10.1021/bi049111r. View

2.
Williams R . Global challenges in liver disease. Hepatology. 2006; 44(3):521-6. DOI: 10.1002/hep.21347. View

3.
Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y . Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2009; 17(3):185-91. DOI: 10.1111/j.1365-2893.2009.01163.x. View

4.
Zhu Q, Oei Y, Mendel D, Garrett E, Patawaran M, Hollenbach P . Novel robust hepatitis C virus mouse efficacy model. Antimicrob Agents Chemother. 2006; 50(10):3260-8. PMC: 1610068. DOI: 10.1128/AAC.00413-06. View

5.
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N . Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res. 2009; 39(5):432-8. DOI: 10.1111/j.1872-034X.2008.00477.x. View